ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results

ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results

  • ABX464 second Phase IIa (HIV/AIDS) on track, top line data expected before year end 2016
  • Lead compoundagainst Chikungunya identified using ABIVAX’ proprietary anti-viral platform
  • Lead compound against Ebola identified using ABIVAX’ polyclonal antibody  technology platforms
  • Robust cash position (28,1 M€) expected to cover ABIVAX financial needs at least until the end of 2017

Paris, September 20th 2016 -  ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease , today provides a corporate update and reports its half-year financial results as of June 30 2016. The half-year financial report is available on the company’s website (Investors – Financial Reports). In compliance with regulations, the half-year financial results were reviewed, on a limited basis, by the company’s statutory auditors and were approved by ABIVAX’s Board of Directors on September 19th.

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41